Fmr LLC increased its holdings in Geron Co. (NASDAQ:GERN) by 158.4% during the 4th quarter, HoldingsChannel reports. The fund owned 15,536,850 shares of the biopharmaceutical company’s stock after acquiring an additional 9,523,953 shares during the quarter. Fmr LLC owned about 0.08% of Geron worth $15,537,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Amalgamated Bank acquired a new stake in Geron during the fourth quarter valued at approximately $25,000. IHT Wealth Management LLC acquired a new stake in Geron during the fourth quarter valued at approximately $37,000. HRT Financial LLC raised its stake in Geron by 192.6% during the fourth quarter. HRT Financial LLC now owns 40,098 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 26,393 shares in the last quarter. SVA Plumb Wealth Management LLC raised its stake in Geron by 98.8% during the fourth quarter. SVA Plumb Wealth Management LLC now owns 50,300 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 25,000 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in Geron by 99.6% during the fourth quarter. SG Americas Securities LLC now owns 56,479 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 28,181 shares in the last quarter. Institutional investors and hedge funds own 33.54% of the company’s stock.
Several analysts have issued reports on the company. Zacks Investment Research upgraded Geron from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 4th. BidaskClub upgraded Geron from a “hold” rating to a “buy” rating in a research note on Saturday, March 16th. ValuEngine cut Geron from a “hold” rating to a “sell” rating in a research note on Monday, December 17th. BTIG Research assumed coverage on Geron in a research note on Tuesday, February 12th. They set a “buy” rating and a $4.00 price objective on the stock. Finally, B. Riley upgraded Geron from a “neutral” rating to a “buy” rating and upped their price objective for the company from $1.50 to $3.25 in a research note on Thursday, January 31st. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $3.39.
Shares of NASDAQ GERN opened at $1.69 on Friday. Geron Co. has a 52-week low of $0.95 and a 52-week high of $6.99.
Geron (NASDAQ:GERN) last announced its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.05). The firm had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $0.22 million. Geron had a negative return on equity of 17.61% and a negative net margin of 2,534.43%. On average, analysts predict that Geron Co. will post -0.34 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Geron Co. (GERN) Position Lifted by Fmr LLC” was originally published by Stock Observer and is the sole property of of Stock Observer. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.thestockobserver.com/2019/03/24/geron-co-gern-position-lifted-by-fmr-llc.html.
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.
Featured Article: How do investors use RSI to grade stocks?
Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geron Co. (NASDAQ:GERN).
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.